1. Home
  2. In Vitro Diagnostics
  3. Autoimmune Diseases
  4. Anti-Lactoferrin

Anti-Lactoferrin

Anti-Lactoferrin is an indirect solid phase enzyme immunometric assay (ELISA). It is designed for the quantitative determination of anti-neutrophil cytoplasmic antibodies (ANCA) directed against Lactoferrin

Regulatery Status: RUO
Catalog No Size
Product Catalog No: EIA-3602 Pack Size: 96 Wells

Pack Size:
Pack Size:
Pack Size:
Pack Size:

Category:
Test Principle

Anti-Lactoferrin is an indirect solid phase enzyme immunometric assay (ELISA). It is designed for the quantitative determination of anti-neutrophil cytoplasmic antibodies (ANCA) directed against Lactoferrin. The assays recognise IgG class autoantibodies. The microplate is coated with Lactoferrin. The microplate can be divided into 12 modules of 8 wells each or can be used completely for 96 determinations. Each well can be separated from the module (“break-away”).

Order Enquiry

    Order Enquiry Form

    References
    1. Hauschild, S.; Schmitt, W.H.; Csernok, E.; Flesch, B. K.; Rautmann, A.; Gross, W.L.. ANCA in systemic vasculitides, collagen vascular diseases, rheumatic disorders and inflammatory bowel diseases. ANCA-associated Vasculitides: Immunological and clinical aspects. Edited by W. L. Gross, Plenum Press, New York, 1993, pp. 245 – 251.
    2. Schmitt, W.H.; Csernok, E.; Flesch, B. K.; Hauschild, Gross, W.L.. Autoantibodies directed against Lysozyme: A new target Antigen for anti-neutrophil cytoplasmatic antibodies (ANCA). ANCA-associated Vasculitides: Immunological and clinical aspects. Edited by W. L. Gross, Plenum Press, New York, 1993, 267 – 272.
    3. Skogh, T. and Peen, E. Lactoferrin, Anti-Lactoferrin antibodies and inflammatory disease. ANCAassociated Vasculitides: Immunological and clinical aspects. Edited by W. L. Gross, Plenum Press, New York, 1993, pp. 533 – 538. Stoffel, M. P.; Csernok, E.; Herzberg, C.; Johnston, T.; Carroll, S.F. and Gross, W. L. Anti-neutrophil cytoplasmatic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders. Clin Exp. Immunol. 1996, No. 104, pp. 54 – 59.
    4. Zhao, M. H.; Jayne, D. R. W.; Ardiles, L. G.; Culley, F.; Hodson, M.E. and Lockwood. Autoantibodies against bactericidal /permeabilty increasing protein in patients with cystic fibrosis. J. Med. 1996, No. 89, pp. 259 – 265.
    5. Wiik, A.; Stumman, L.; Kjeldsen, L.; Borregaard, N.; Ullman, S.; Jacobsen, S. and Halberg, P. The diversity of perinuclear antineutrophil cytoplasmic antibodies (pANCA) antigens. Proceedings of the 6th international ANCA workshop, France – July 1995, pp. 15 – 17.
    6. Jenette, J. C. and Falk, R. J. Antineutrophil cytoplasmic autoantibodies and associated diseas: A review. Am. J. of Kidney Disease 1990, Vol XV, No. 6, pp. 517 – 529.
    7. Schmitt, W. H. and Gross, W. L. Antineutrophile zytoplasmatische Antikörper (ANCA). Internist 1995, No. 36, pp. 282 – 290. Gross, W. L. and Rheinhold-Keller, E.. ANCA-assoziierte Vaskulitiden (Wegener Granulomatose, Churg-Strauß-Syndrom, Mikroskopische Polyangiitis) – 1. Systematik, Pathogenese and Klinik. Z. Rheumatol (1995), No. 54, pp. 279 – 290.
    8. de Grot, K.; Schnabel, A. and Gross, W. L. ANCA-assoziierte Vaskulitiden (Wegener Granulomatose, Churg-Strauß-Syndrom, Mikroskopische Polyangiitis) – 1. Diagnostisches Procedere. Z. Rheumatol (1995), No. 54, pp. 291 – 302.
    Documents
    Enquiry